Viromed Medical AG, DE000A3MQR65

Viromed Medical AG / DE000A3MQR65

20.12.2024 - 14:05:38

Viromed Medical AG completes acquisition of pharmedix GmbH

EQS-Ad-hoc: Viromed Medical AG / Key word(s): Takeover/Mergers & Acquisitions


20-Dec-2024 / 14:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Notarial purchase agreement signed today Consolidated revenues are expected to multiply to a low double-digit million euro amount in fiscal year 2025. Pinneberg, 20 December 2024 – Today, Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) completed the announced acquisition of pharmedix GmbH by notarized purchase agreement. The acquisition is effective as of 1 January 2025. Following the successful acquisition of pharmedix GmbH, Viromed Medical AG now expects consolidated revenues in the low double-digit million euro range for the 2025 financial year, a significant increase over the previous year.   Contact Viromed Medical AG Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de


End of Inside Information

20-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg
EQS News ID: 2056023

 
End of Announcement EQS News Service

2056023  20-Dec-2024 CET/CEST
fncls.ssp?fn=show_t_gif&application_id=2056023&application_name=news&site_id=trading_house_net~~~7efceac5-959a-43d6-afef-21ad42b6a5d4
@ dgap.de